- Home
- NPKI vs AUTL Comparison
NPKI vs AUTL Comparison
Compare NPKI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- AUTL
- Stock Information
- Founded
- NPKI 1932
- AUTL 2014
- Country
- NPKI United States
- AUTL United Kingdom
- Employees
- NPKI N/A
- AUTL N/A
- Industry
- NPKI Metal Fabrications
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NPKI Industrials
- AUTL Health Care
- Exchange
- NPKI Nasdaq
- AUTL Nasdaq
- Market Cap
- NPKI 722.7M
- AUTL 625.4M
- IPO Year
- NPKI N/A
- AUTL 2018
- Fundamental
- Price
- NPKI $8.56
- AUTL $2.26
- Analyst Decision
- NPKI Strong Buy
- AUTL Strong Buy
- Analyst Count
- NPKI 1
- AUTL 5
- Target Price
- NPKI $12.00
- AUTL $9.32
- AVG Volume (30 Days)
- NPKI 933.2K
- AUTL 2.0M
- Earning Date
- NPKI 08-04-2025
- AUTL 08-07-2025
- Dividend Yield
- NPKI N/A
- AUTL N/A
- EPS Growth
- NPKI N/A
- AUTL N/A
- EPS
- NPKI N/A
- AUTL N/A
- Revenue
- NPKI $233,299,000.00
- AUTL $9,011,000.00
- Revenue This Year
- NPKI $15.28
- AUTL $461.76
- Revenue Next Year
- NPKI $9.62
- AUTL $112.66
- P/E Ratio
- NPKI $18.12
- AUTL N/A
- Revenue Growth
- NPKI 312.30
- AUTL N/A
- 52 Week Low
- NPKI $4.76
- AUTL $1.11
- 52 Week High
- NPKI $8.88
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- NPKI N/A
- AUTL 60.43
- Support Level
- NPKI N/A
- AUTL $2.20
- Resistance Level
- NPKI N/A
- AUTL $2.44
- Average True Range (ATR)
- NPKI 0.00
- AUTL 0.12
- MACD
- NPKI 0.00
- AUTL -0.01
- Stochastic Oscillator
- NPKI 0.00
- AUTL 61.29
About NPKI NPK International Inc. Common Stock
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.